A mutant hepatitis B virus core protein mimics inhibitors of icosahedral capsid self-assembly.
Understanding self-assembly of icosahedral virus capsids is critical to developing assembly directed antiviral approaches and will also contribute to the development of self-assembling nanostructures. One approach to controlling assembly would be through the use of assembly inhibitors. Here we use Cp149, the assembly domain of the hepatitis B virus capsid protein, together with an assembly defective mutant, Cp149-Y132A, to examine the limits of the efficacy of assembly inhibitors. By itself, Cp149-Y132A will not form capsids. However, Cp-Y132A will coassemble with the wild-type protein on the basis of light scattering and size exclusion chromatography. The resulting capsids appear to be indistinguishable from normal capsids. However, coassembled capsids are more fragile, with disassembly observed by chromatography under mildly destabilizing conditions. The relative persistence of capsids assembled under conditions where association energy is weak compared to the fragility of those where association is strong suggests a mechanism of "thermodynamic editing" that allows replacement of defective proteins in a weakly associated complex. There is fine line between weak assembly, where assembly defective protein is edited from a growing capsid, and relatively strong assembly, where assembly defective subunits may dramatically compromise virus stability. Thus, attempts to control virus self-assembly (with small molecules or defective proteins) must take into account the competing process of thermodynamic editing.
Bourne
Christina R
CR
Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma 73104, USA.
Katen
Sarah P
SP
Fulz
Matthew R
MR
Packianathan
Charles
C
Zlotnick
Adam
A
D000998:Antiviral Agents / Q000494:pharmacology*; D002213:Capsid / Q000187:drug effects / Q000378:metabolism* / Q000648:ultrastructure; D019281:Dimerization; D006515:Hepatitis B virus / Q000187:drug effects / Q000502:physiology* / Q000648:ultrastructure; D057927:Hydrophobic and Hydrophilic Interactions; D007700:Kinetics; D008958:Models, Molecular; D050505:Mutant Proteins / Q000378:metabolism; D009154:Mutation / Q000235:genetics*; D014758:Viral Core Proteins / Q000378:metabolism*; D019065:Virus Assembly / Q000187:drug effects*
D000998:Antiviral Agents; D050505:Mutant Proteins; D014758:Viral Core Proteins